Abstract: A system for mounting to a post including: (1) a mounting surface perpendicular to the post having a planar top side and an opposing bottom side; and (2) a hollow structure extending from the bottom side of the mounting surface and having an interior opening, wherein the hollow structure further includes: (a) a lower end positioned distal the mounting surface, (b) a first lip positioned about a first perimeter of the interior opening, and (c) a second lip positioned about a second perimeter of the interior opening, wherein the length of the first perimeter is greater than the length of the second perimeter, and wherein the first lip is positioned between the second lip and the lower end and the second lip is positioned between the first lip and the mounting surface.

Abstract: An apparatus for balancing a fan or other spinning product may comprise a motor for spinning the fan, an accelerometer for gathering sampling data from the fan while it is spinning, a laser source, a laser redirection platform comprising a spinning mirror configured to track the rotational speed of the spinning fan, and a control module. The fan and laser redirection platform may each have an index hole for tracking, using respective photocell transmitters and receivers, rotational speed and phase. The control module may direct the fan motor to spin up the fan, collect balance data, and determine a location on the fan for burning a hole to correct imbalance. The control module may direct the laser redirection platform to spin at the same rpm as the fan, and such that a laser redirection mirror directs a laser beam from the laser source toward the target burn location on the fan.

Abstract: The invention relates to novel quinazolines and heterocycles which are antagonists or positive modulators of AMPA receptors, and the use thereof for treating, preventing or ameliorating neuronal loss associated with stroke, global and focal ischemia, CNS trauma, hypoglycemia and surgery, as well as treating or ameliorating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease and Down's syndrome, treating, preventing or ameliorating the adverse consequences of the overstimulation of the excitatory amino acids, treating, preventing or ameliorating anxiety, psychosis, convulsions, chronic pain, glaucoma, retinitis, urinary incontinence, muscular spasm and inducing anesthesia, as well as for treating or ameliorating the adverse consequences of excitatory amino acid deficiency such as schizophrenia, myoclonus, Alzheimer's disease and malnutrition and neural maldevelopment, and as cognition and learning enhancers.

Abstract: A conventional water conditioner includes a tank having a side wall, closed bottom and top ends, an opening in the top end, receiving and discharging material, a control valve assembly over said opening for introducing material into the tank and discharging material therefrom, a bed of particulate material for conditioning water and a dip tube extending downwardly from the assembly into the bed of particulate material. An umbrella-shaped distributor with a plurality of openings therein ensures that material entering the top of the tank around the dip tube is evenly distributed over the top surface of the bed. A bottom distributor defined by radially extending tubes ensures even distribution of liquid during the backwash cycle.

Abstract: The invention relates to novel quinazolines and heterocycles which are antagonists or positive modulators of AMPA receptors, and the use thereof for treating, preventing or ameliorating neuronal loss associated with stroke, global and focal ischemia, CNS trauma, hypoglycemia and surgery, as well as treating or ameliorating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease and Down's syndrome, treating, preventing or ameliorating the adverse consequences of the overstimulation of the excitatory amino acids, treating, preventing or ameliorating anxiety, psychosis, convulsions, chronic pain, glaucoma, retinitis, urinary incontinence, muscular spasm and inducing anesthesia, as well as for treating or ameliorating the adverse consequences of excitatory amino acid deficiency such as schizophrenia, myoclonus, Alzheimer's disease and malnutrition and neural maldevelopment, and as cognition and learning enhancers.

Abstract: The invention relates to novel quinazolines and heterocycles which are antagonists or positive modulators of AMPA receptors, and the use thereof for treating, preventing or ameliorating neuronal loss associated with stroke, global and focal ischemia, CNS trauma, hypoglycemia and surgery, as well as treating or ameliorating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease and Down's syndrome, treating, preventing or ameliorating the adverse consequences of the overstimulation of the excitatory amino acids, treating, preventing or ameliorating anxiety, psychosis, convulsions, chronic pain, glaucoma, retinitis, urinary incontinence, muscular spasm and inducing anesthesia, as well as for treating or ameliorating the adverse consequences of excitatory amino acid deficiency such as schizophrenia, myoclonus. Alzheimer's disease and malnutrition and neural maldevelopment, and as cognition and learning enhancers.

Abstract: The invention relates to substituted 2,3-benzodiazepin-4-ones which are antagonists or positive modulators of AMPA receptors, and the use thereof for treating, preventing or ameliorating neuronal loss associated with stroke, global and focal ischemia, CNS trauma, hypoglycemia and surgery, as well as treating or ameliorating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease and Down's syndrome, treating, preventing or ameliorating the adverse consequences of the overstimulation of the excitatory amino acids, treating or ameliorating anxiety, psychosis, convulsions, chronic pain, glaucoma, CMV retinitis, urinary incontinence, muscular spasm and inducing anesthesia, as well as for treating or ameliorating the adverse consequences of excitatory amino acid deficiency such as schizophrenia, Alzheimer's disease and malnutrition and neural maldevelopment, and as cognition enhancers.

Abstract: Methods for the efficient preparation of 7-hydroxy-1,2,3,4-tetrahydroquinoline include a first method in which the acylation of m-aminophenol obtains a lactam which is reduced to give the desired quinoline and a second method in which tetrahydroquinoline is nitrated and hydrogenated and then hydrolyzed to obtain the desire quinoline. 7-hydroxy-1,2,3,4-tetrahydroquinoline is used in the efficient synthesis of four lasing dyes of the rhodamine class.